Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

ABSTRACT:

Background

The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.

Methods

We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, axillary node-negative breast cancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breast cancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence w

SUBMITTER: Sparano JA 

PROVIDER: S-EPMC6709671 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature